Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 86-92

  Oryoji, Kensuke ^a   Kiyohara, Chikako ^a   Horiuchi, Takahiko ^a   Tsukamoto, Hiroshi ^a   Niiro, Hiroaki ^a   Shimoda, Terufumi ^b   Akashi, Koichi ^a   Yanase, Toshihiko ^c  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA NATIONAL HOSPITAL   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Carotid intima media thickness; Cyclosporine A; Risk factor; Systemic lupus erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TACROLIMUS; WARFARIN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DOSE RESPONSE; DRUG PULSE THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SLEDAI; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ATHEROSCLEROSIS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84896954249     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.852838     Document Type: Article

References (36)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60:221-5.
2. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001;13:345-51.
3. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44:2331-7.
4. Manzi S, Urbach AH, McCune AB, et al. Systemic lupus erythematosus in a boy with chronic granulomatous disease: case report and review of the literature. Arthritis Rheum. 1991;34:101-5.
5. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-Analysis. Circulation. 2007;115:459-67.
6. Yanase T, Nasu S, Mukuta Y, et al. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens. 2006;19:1206-12.
7. Nohara R, Daida H, Hata M, et al. Effect of intensive lipidlowering therapy with rosuvastatin on progression of carotid intima-media thickness in Japanese patients: justification for Atherosclerosis Regression Treatment (JART) study. Circ J. 2012;76:221-9.
8. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992;35:630-40.
10. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39: 363-9.
11. MHLW. 2008 [updated 2008; cited]. http://www.mhlw.go.jp/bunya/kenkou/ eiyou/h20-houkoku.html.
12. Chaiamnuay S, Bertoli AM, Fernandez M, et al. The impact of increased body mass index on systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA XLVI) [corrected]. J Clin Rheumatol. 2007;13:128-33.
13. Colombo BM, Murdaca G, Ciprandi G, Sormani MP. Body mass index in Th1 and Th2 diseases. Immunol Lett. 2008;117:119-20.
14. Gaitonde S, Samols D, Kushner I. C-reactive protein and systemic lupus erythematosus. Arthritis Rheum. 2008;59:1814-20.
15. Roy S, Tan KT. Pyrexia and normal C-reactive protein (CRP) in patients with systemic lupus erythematosus: always consider the possibility of infection in febrile patients with systemic lupus erythematosus regardless of CRP levels. Rheumatology (Oxford). 2001;40:349-50.
16. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399-406.
17. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104:1887-93.
18. Ugurlu S, Seyahi E, Cetinkaya F, Ozbakir F, Balci H, Ozdogan H. Intima-media thickening in patients with familial Mediterranean fever. Rheumatology (Oxford). 2009;48:911-5.
19. Zhang CY, Lu LJ, Li FH, et al. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. J Clin Rheumatol. 2009;15:111-6.
20. Bicakcigil M, Tasan D, Tasdelen N, Mutlu N, Yavuz S. Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients. Lupus. 2011;20:1063-71.
21. Jimenez S, Garcia-Criado MA, Tassies D, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford). 2005;44: 756-61.
22. Sari I, Karaoglu O, Can G, et al. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol. 2007;26:1467-73.
23. Thompson T, Sutton-Tyrrell K, Wildman RP, et al. Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum. 2008;58:835-42.
24. Rossi M, Mosca M, Tani C, Franzoni F, Santoro G, Bombardieri S. Integrated backscatter analysis of carotid intima-media complex in patients with systemic lupus erythematosus. Clin Rheumatol. 2008;27:1485-8.
25. Santos MJ, Pedro LM, Canhao H, et al. Hemorheological parameters are related to subclinical atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis patients. Atherosclerosis. 2011;219:821-6.
26. Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1994;14:1098-104.
27. Crouse JR, Goldbourt U, Evans G, et al. Risk factors and segment-specific carotid arterial enlargement in the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1996;27:69-75.
28. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol. 1996;16:984-91.
29. Folsom AR, Pankow JS, Williams RR, Evans GW, Province MA, Eckfeldt JH. Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost. 1998;79:400-4.
30. Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimalmedial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation. 2001;104:2815-9.
31. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med. 1999;340:115-26.
32. Kallenberg CG, Heeringa P. Pathogenesis of vasculitis. Lupus. 1998;7:280-4.
33. Doria A, Shoenfeld Y, Wu R, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2003;62:1071-7.
34. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136-42.
35. Maes BD, Vanrenterghem YF. Cyclosporine: advantages versus disadvantages vis-A-vis tacrolimus. Transpl Proc. 2004;36:40S-9S.
36. Sazliyana S, Mohd Shahrir MS, Kong CT, Tan HJ, Hamidon BB, Azmi MT. Implications of immunosuppressive agents in cardiovascular risks and carotid intima media thickness among lupus nephritis patients. Lupus. 2011;20:1260-6.